Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy.

Saijo, Masayuki

Saijo, Masayuki.

Affiliation

Saijo M; Department of Virology 1, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku, Tokyo, 162-8640, Japan. Electronic address: msaijo@nih.go.jp.

J Infect Chemother ; 24(10): 773-781, 2018 Oct.

Article in En | MEDLINE | ID: mdl-30098914

Subject(s)

Amides/therapeutic use; Antiviral Agents/therapeutic use; Bunyaviridae Infections/drug therapy; Phlebovirus/pathogenicity; Pyrazines/therapeutic use; Thrombocytopenia/drug therapy; Aged, 80 and over; Animals; Bunyaviridae Infections/epidemiology; Bunyaviridae Infections/pathology; Bunyaviridae Infections/prevention & control; China/epidemiology; Female; Humans; Japan/epidemiology; Male; Mice; Mice, Knockout; Middle Aged; Mortality; Republic of Korea/epidemiology; Syndrome; Thrombocytopenia/epidemiology; Thrombocytopenia/pathology; Thrombocytopenia/prevention & control

Key words

Favipiravir; Pathophysiology; Ribavirin; SFTS; Severe fever with thrombocytopenia syndrome; Viral hemorrhagic fever

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Thrombocytopenia / Phlebovirus / Bunyaviridae Infections / Amides Type of study: Prognostic_studies Limits: Aged80 / Animals / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google